These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16457161)

  • 1. [Cost effectiveness analysis of two adjuvant regimens in the treatment of colorectal cancer: an interpretation of the MOSAIC Study].
    Rebesco B; Cantagalli E; Amalfitano ME
    Tumori; 2005; 91(6):suppl 1-10. PubMed ID: 16457161
    [No Abstract]   [Full Text] [Related]  

  • 2. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation).
    Hochster HS
    Clin Adv Hematol Oncol; 2005 May; 3(5):405-6. PubMed ID: 16167014
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T; Takeuchi T; Fukuda T; Shimozuma K; Ohashi Y
    Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Cassidy J; Schmoll HJ; Van Cutsem E
    J Clin Oncol; 2008 May; 26(13):2226-7; author reply 2228. PubMed ID: 18445855
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
    Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
    Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
    Pettersson K; Carlsson G; Holmberg C; Sporrong SK
    Acta Oncol; 2012 Sep; 51(7):840-8. PubMed ID: 22937953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
    J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin (Eloxatin) for advanced colon cancer.
    Med Lett Drugs Ther; 2003 Jan; 45(1148):7-8. PubMed ID: 12571541
    [No Abstract]   [Full Text] [Related]  

  • 10. Oxaliplatin: a welcome addition to our therapeutic armamentarium.
    Chu E
    Clin Colorectal Cancer; 2002 Aug; 2(2):72. PubMed ID: 12453318
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
    Wen F; Yao K; Du ZD; He XF; Zhang PF; Tang RL; Li Q
    World J Gastroenterol; 2014 Dec; 20(47):17976-84. PubMed ID: 25548497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
    Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
    Goldstein DA; El-Rayes BF
    Oncologist; 2015 Sep; 20(9):981-2. PubMed ID: 26265225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
    Vaiani M; Trippoli S; Messori A
    N Engl J Med; 2001 Jan; 344(4):305-6; author reply 306-7. PubMed ID: 11191660
    [No Abstract]   [Full Text] [Related]  

  • 15. [Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis].
    Shida T; Endo Y; Shiraishi T; Yoshioka T; Suzuki K; Kobayashi Y; Ono Y; Ito T; Inoue T
    Yakugaku Zasshi; 2018; 138(1):83-90. PubMed ID: 29311468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
    Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
    Miyazaki Y; Harada T; Akase T; Arakawa I; Inoue T
    Clin Ther; 2009; 31 Pt 2():2433-41. PubMed ID: 20110051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Surgery and chemotherapy for colorectal cancer: current status and perspective].
    Kawamura Y; Konishi F
    Nihon Shokakibyo Gakkai Zasshi; 2007 Jul; 104(7):1018-24. PubMed ID: 17611378
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
    Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
    Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of adjuvant therapy for colorectal cancer.
    O'Connell MJ
    Oncology (Williston Park); 2004 May; 18(6):751-5; discussion 755-8. PubMed ID: 15214594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.